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Figure 1. Comparison of Contrast Washout Between Early and Delayed CT
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Pre-Dismissal Surveillance
Echocardiography Second Day
After TAVR
Transcatheter aortic valve implantation (TAVI) has been recog-
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a Representative Case of Coronary Plaque Delayed Enhancement
y (CT) acquisitions in the aortic lumen (left) and within coronary atherosclerotic
B) Delayed enhancement of a high-risk coronary plaque. A 61-year-old male, with
nt coronary CT angiography that revealed a stenosis with 75% luminal diameter
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t contrast washout was 2.4% in the proximal lesion and 6.3% in the distal
1.3 and low attenuation plaque 30 HU).and
aph
res. (
rwe
rona
rcennized as an alternative treatment for high-risk surgical patients
p
p
a
(
s
S
l
w
g
a
O
p
m
s
e
d
i
r
I
o
i
m
t
V
r
b
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 1 , 2 0 1 2
N O V E M B E R 2 0 1 2 : 1 1 8 1 – 6
Letters to the Editor 1183with symptomatic severe aortic stenosis (AS). Valve migration is
a potentially life-threatening complication of TAVI that usually
occurs during implantation. Late (24 h) (1) migration may
result in catastrophic complications like cardiogenic shock (1) or
heart failure (2). We recently encountered a case of a valve
migration into the left ventricular outflow tract (LVOT) iden-
tified on a routine 24-h follow-up echocardiogram in an asymp-
tomatic patient.
A 77-year-old man with symptomatic severe AS and high risk
for surgical replacement (European System for Cardiac Operative
Risk Evaluation score 20%; Society of Thoracic Surgeons score
17%) underwent TAVI. Baseline echocardiogram revealed a
calcified trileaflet aortic valve (AV), AV area 0.87 cm2, mean
ressure gradient 27 mm Hg, and LV ejection fraction 30%. The
atient underwent TAVI in standard fashion with transfemoral
pproach. Intraprocedural transesophageal echocardiogram
TEE) confirmed the aortic annulus diameter of 23 mm. As
uch, a 26 mm balloon-expandable bioprosthesis (Edwards-
APIEN, Edwards Lifesciences, Irvine, California) was se-
ected. After the native AV balloon pre-dilation, the TAVI valve
Figure 1. Migration of TAVI Bioprosthesis Into LVOT in an Asymptomatic P
Immediately post-transcatheter aortic valve implantation (TAVI), optimal valve p
echocardiography (B) (Online Video 2) with a moderate eccentric periprosthetic
echocardiogram performed 24 h post–TAVI demonstrated thickened native leaﬂ
left ventricular outﬂow tract (LVOT) (C) (Online Video 4). Severe central regurgit
thetic valve migration with a simultaneous functioning of the native and prosthetic
ing an emergent open-heart surgery, the bioprosthesis was found fully expand
with moderate calciﬁcation at the tips and trivially calciﬁed annulus (E).as advanced to the annulus using fluoroscopic and TEE
uidance and deployed under rapid pacing. Post-deployment,
ortogram TEE (Fig. 1A, Online Video 1) and TEE (Fig. 1B,
nline Video 2) confirmed optimal valve position. The mean
ressure gradient was 9 mm Hg. There was a single jet of
oderate eccentric periprosthetic regurgitation (Online Video 3). Con-
idering the patient’s hemodynamic stability, no evidence of inad-
quate valve deployment, and a small risk of device displacement or
evelopment of central regurgitation with redilation, no further
ntervention was undertaken.
Transthoracic echocardiogram (TTE) repeated 24 h after TAVI
evealed an increased prosthetic mean pressure gradient (22 mm Hg).
mportantly, partially mobile thickened native leaflets were seen
verlying the prosthetic stent suggesting TAVI valve migration
nto LVOT (Fig. 1C, Online Video 4). In addition to mild-to-
oderate periprosthetic regurgitation, severe central regurgita-
ion ceasing within LVOT was demonstrated (Fig. 1D, Online
ideo 5). Urgent TEE confirmed valve migration into LVOT
esulting in a simultaneous functioning of the native and
ioprosthetic valves (Online Video 6). Full closure of the native
nt
ion was conﬁrmed with ﬂuoroscopy (A) (Online Video 1) and transesophageal
urgitation seen on color Doppler imaging (Online Video 3). Transthoracic
overlying the prosthetic stent suggesting migration of the prosthesis into the
n on color Doppler appeared to cease within LVOT (D) (Online Video 5). Pros-
ves was conﬁrmed on a transesophageal echocardiogram (Online Video 6). Dur-
nd structurally normal. The native aortic valve had 3 relatively ﬂexible cuspsatie
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Letters to the Editor1184valve leaflets was restricted by the prosthetic stent resulting in
severe central regurgitation stopping at the competent biopros-
thetic leaflets. An urgent valve-in-valve TAVI was planned but
repeat TEE demonstrated further valve migration into LVOT
that precluded safe implantation of the second overlapping
prosthesis. The patient underwent an emergent open-heart
surgery during which the TAVI valve was found sitting in
LVOT in an unstable position. The native valve leaflets had 3
relatively flexible cusps with moderate calcification (Fig. 1E).
The aortic annulus had only trivial amount of calcium. The AV
was replaced with 23-mm Perimount Magna (Edwards Life-
sciences) tissue valve. The patient tolerated the surgery well.
Valve dislodgment may occur in patients with less-than-severe
AV and root calcification that may be insufficient for anchoring the
prosthesis (1,2), which was likely the case in our patient. Other
potential causes include stent malposition (3,4) and selection of an
undersized valve (5). In the present case, the correct 26-mm valve
was selected based on 23-mm annulus, and its optimal position was
confirmed with aortogram and TEE. Forces from the peripros-
thetic and central AV regurgitation, and from the residual over-
hanging native AV leaflets (2) likely contributed to the progression
of valve migration.
This case demonstrates that routine 24-h follow-up echocardi-
ography is essential to confirm correct TAVI valve position and
function in order to prevent adverse consequences of delayed
mechanical complications. In addition, it demonstrates that TAVI
should be used with caution in patients with less-than-severe AV
calcification.
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For supplementary videos and their legends, please see the online version of this article.
Effective Dose of PET/CT in
Informed Consent Forms
The recent article by Terranova et al. (1) made important points
about informed consent. We agree with their conclusions that “the
development of simpler and more informative informed consent
models and forms will gently force the doctor to be more aware of
what he/she does and the patient more aware of what he/she
undergoes, enabling both to make more responsible choices” (1).
However, the authors might have begun with the correct facts to
avoid the gross error shown in Figure 3. At the bottom right of that
figure, the dose for rest/stress myocardial perfusion positron emis-
sion tomography (PET) is shown as approximately 1,000 “equiva-
lent number of chest x-rays.” For a visual representation, the
authors reproduced Figure 2A from our prior publication, featured
on the cover of that issue of the Journal of Nuclear Medicine (2). As
we described in the middle of the second column on page 1,113 of
that paper (2), with further detail in Table 2 of a subsequent paper
(3), the dose equivalent from our rest/stress cardiac PET scan using
computed tomography (CT) attenuation correction is approxi-
mately 7.5 mSv (using a low-dose helical CT at rest and a single
post-stress cine CT in addition to the rubidium-82 tracer for PET).
Assuming a standard 0.02-mSv effective dose for a chest x-ray,
our PET/CT scan equals roughly 375 chest x-rays, almost one-
third of the value suggested in their Figure 3 (1). As such, PET/CT
delivers less radiation than other modalities in their Table 3:
single-photon emission computed tomography (SPECT) (using
either technetium-99m or thallium-201), CT angiogram, or per-
cutaneous coronary intervention. As an additional error, the dose-
based order of tests on the x-axis of Figure 3 (invasive angiogram,
SPECT, CT angiogram, PET) differs from their order in Table 3
above it (SPECT with technetium-99m, CT angiogram, invasive
stenting, SPECT with thallium-201). Therefore, Figure 3 was
factually incorrect and failed the authors’ words for “simpler and
more informative informed consent.”
Moreover, quantitative PET perfusion imaging is a powerful
guide to avoid the higher-dose procedures like SPECT imaging
and CT or invasive angiography by quantitatively defining physio-
logical stenosis severity before these procedures are undertaken and
identifying who will optimally benefit from them (4) at the lowest
total radiation dose.
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